Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J, Vijayakumar A, Ghoshal S, Marchand B, Yi S, Kornyeyev D, Zagorska A, Hollenback D, Walker K, Liu K, Pendem S, Newstrom D, Brockett R, Mikaelian I, Kusam S, Ramirez R, Lopez D, Li L, Fuchs BC, Breckenridge DG. Bates J, et al. Among authors: yi s. J Hepatol. 2020 Oct;73(4):896-905. doi: 10.1016/j.jhep.2020.04.037. Epub 2020 May 4. J Hepatol. 2020. PMID: 32376414 Free article.
Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects.
Nelson CH, Etchevers K, Yi S, Breckenridge D, Hepner M, Patel U, Ling J, Mathias A. Nelson CH, et al. Among authors: yi s. Clin Pharmacokinet. 2020 Sep;59(9):1109-1117. doi: 10.1007/s40262-020-00878-y. Clin Pharmacokinet. 2020. PMID: 32333325 Clinical Trial.
Gut microbial genomes with paired isolates from China illustrate probiotic and cardiometabolic effects.
Huang P, Dong Q, Wang Y, Tian Y, Wang S, Zhang C, Yu L, Tian F, Gao X, Guo H, Yi S, Li M, Liu Y, Zhang Q, Lu W, Wang G, Yang B, Cui S, Hua D, Wang X, Jiao Y, Liu L, Deng Q, Ma B, Wu T, Zou H, Shi J, Zhang H, Fan D, Sheng Y, Zhao J, Tang L, Zhang H, Sun W; CGMR Consortium; Chen W, Kong X, Chen L, Zhai Q. Huang P, et al. Among authors: yi s. Cell Genom. 2024 May 6:100559. doi: 10.1016/j.xgen.2024.100559. Online ahead of print. Cell Genom. 2024. PMID: 38740021 Free article.
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S, Xiong A, Yu J, Wang X, Han B, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. Ren S, et al. Among authors: yi s. Cancer Immunol Immunother. 2024 May 10;73(7):124. doi: 10.1007/s00262-024-03715-4. Cancer Immunol Immunother. 2024. PMID: 38727837 Free PMC article. Clinical Trial.
4,303 results